A Phase II Trial to Assess the Safety, Immunological Activity of TroVax Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Trial Profile

A Phase II Trial to Assess the Safety, Immunological Activity of TroVax Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs MVA 5T4 (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SKOPOS
  • Most Recent Events

    • 13 Nov 2015 Status changed from recruiting to completed, according to United Kingdom Clinical Research Network.
    • 13 Nov 2015 Planned End Date changed from 31 Jul 2015 to 27 Aug 2015, according to United Kingdom Clinical Research Network.
    • 09 Nov 2015 Data from this trial is expected to be published in a peer-reviewed journal in 2016, according to an Oxford BioMedica media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top